{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:09:03Z","timestamp":1791223743925,"version":"4.1.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T00:00:00Z","timestamp":1745712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40120-025-00744-8","type":"journal-article","created":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T13:01:24Z","timestamp":1745758884000},"page":"1007-1022","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in Australian Hospitals"],"prefix":"10.1007","volume":"14","author":[{"given":"Ian R.","family":"Woodcock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didu S.","family":"Kariyawasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maina P.","family":"Kava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eppie M.","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colman","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J. C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,27]]},"reference":[{"key":"744_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-genom-102319-103602","volume":"21","author":"B Wirth","year":"2020","unstructured":"Wirth B, Karakaya M, Kye MJ, Mendoza-Ferreira N. Twenty-five years of spinal muscular atrophy research: from phenotype to genotype to therapy, and what comes next. Annu Rev Genom Hum Genet. 2020;21:231\u201361.","journal-title":"Annu Rev Genom Hum Genet"},{"key":"744_CR2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review. Orphanet J Rare Dis. 2017;12:124.","journal-title":"Orphanet J Rare Dis"},{"key":"744_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2377-11-36","volume":"11","author":"IA Darbar","year":"2011","unstructured":"Darbar IA, Plaggert PG, Resende MB, et al. Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurol. 2011;11:36.","journal-title":"BMC Neurol"},{"key":"744_CR4","first-page":"895","volume":"15","author":"RS Anderton","year":"2015","unstructured":"Anderton RS, Mastaglia FL. Advances and challenges in developing a therapy for spinal muscular atrophy. Expert Rev Neurother. 2015;15:895\u2013908.","journal-title":"Expert Rev Neurother"},{"key":"744_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82:883\u201391.","journal-title":"Ann Neurol"},{"key":"744_CR6","unstructured":"Spinraza. Prescribing information. Cambridge, MA: Biogen, Inc., April 2024. https:\/\/www.spinraza.com\/content\/dam\/commercial\/spinraza\/caregiver\/en_us\/pdf\/spinraza-prescribing-information.pdf. Accessed Feb 2025."},{"key":"744_CR7","unstructured":"Evrysdi. Prescribing information. South San Francisco, CA: Genentech, Inc., February 2025. https:\/\/www.gene.com\/download\/pdf\/evrysdi_prescribing.pdf. Accessed Feb 2025."},{"key":"744_CR8","unstructured":"Zolgensma. Prescribing information. Bannockburn, IL: Novartis Gene Therapies, Inc., February 2025. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/zolgensma.pdf. Accessed Feb 2025."},{"key":"744_CR9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/ijns10030056","volume":"10","author":"K Cooper","year":"2024","unstructured":"Cooper K, Nalbant G, Sutton A, et al. Systematic review of presymptomatic treatment for spinal muscular atrophy. Int J Neonatal Screen. 2024;10:56.","journal-title":"Int J Neonatal Screen"},{"key":"744_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.nmd.2021.03.007","volume":"31","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Vr\u0161\u010daj E, Servais L, Osredkar D, SMA NBS World Study Group. Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord. 2021;31:574\u201382.","journal-title":"Neuromuscul Disord"},{"key":"744_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fpubh.2015.00214","volume":"3","author":"SC Metternick-Jones","year":"2015","unstructured":"Metternick-Jones SC, Lister KJ, Dawkins HJ, et al. Review of current international decision-making processes for newborn screening: lessons for Australia. Front Public Health. 2015;3:214.","journal-title":"Front Public Health"},{"key":"744_CR12","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","volume":"92","author":"ST Shih","year":"2021","unstructured":"Shih ST, Farrar MA, Wiley V, Chambers G. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry. 2021;92:1296\u2013304.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"744_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/dmcn.15117","volume":"64","author":"AM D\u2019Silva","year":"2022","unstructured":"D\u2019Silva AM, Kariyawasam DST, Best S, et al. Integrating newborn screening for spinal muscular atrophy into health care systems: an Australian pilot programme. Dev Med Child Neurol. 2022;64:625\u201332.","journal-title":"Dev Med Child Neurol"},{"key":"744_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100742","volume":"33","author":"DST Kariyawasam","year":"2021","unstructured":"Kariyawasam DST, D\u2019Silva AM, Vetsch J, et al. \u201cWe needed this\u201d: perspectives of parents and healthcare professionals involved in a pilot newborn screening program for spinal muscular atrophy. EClinicalMedicine. 2021;33: 100742.","journal-title":"EClinicalMedicine"},{"key":"744_CR15","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2147\/DDDT.S214174","volume":"16","author":"HT Hjartarson","year":"2022","unstructured":"Hjartarson HT, Nathorst-B\u00f6\u00f6s K, Sejersen T. Disease modifying therapies for the management of children with spinal muscular atrophy (5q SMA): an update on the emerging evidence. Drug Des Devel Ther. 2022;16:1865\u201383.","journal-title":"Drug Des Devel Ther"},{"key":"744_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.20517\/rdodj.2023.30","volume":"2","author":"C Ji","year":"2023","unstructured":"Ji C, Farrar MA, Norris S, et al. The Australian landscape of newborn screening in the genomics era. Rare Dis Orphan Drugs J. 2023;2:26.","journal-title":"Rare Dis Orphan Drugs J"},{"key":"744_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ijns8030045","volume":"8","author":"STF Shih","year":"2022","unstructured":"Shih STF, Keller E, Wiley V, et al. Modelling the cost-effectiveness and budget impact of a newborn screening program for spinal muscular atrophy and severe combined immunodeficiency. Int J Neonatal Screen. 2022;8:45.","journal-title":"Int J Neonatal Screen"},{"key":"744_CR18","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jval.2022.06.010","volume":"25","author":"R Velikanova","year":"2022","unstructured":"Velikanova R, van der Schans S, Bischof M, et al. Cost-effectiveness of newborn screening for spinal muscular atrophy in The Netherlands. Value Health. 2022;25:1696\u2013704.","journal-title":"Value Health"},{"key":"744_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.31128\/AJGP-03-21-5924","volume":"51","author":"JE Davidson","year":"2022","unstructured":"Davidson JE, Farrar MA. The changing therapeutic landscape of spinal muscular atrophy. Aust J Gen Pract. 2022;51:38\u201342.","journal-title":"Aust J Gen Pract"},{"key":"744_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1098-1004(200003)15:3<228::AID-HUMU3>3.0.CO;2-9","volume":"15","author":"B Wirth","year":"2000","unstructured":"Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15:228\u201337.","journal-title":"Hum Mutat"},{"key":"744_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","volume":"7","author":"DS Kariyawasam","year":"2023","unstructured":"Kariyawasam DS, D\u2019Silva AM, Sampaio H, et al. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study. Lancet Child Adolesc Health. 2023;7:159\u201370.","journal-title":"Lancet Child Adolesc Health"},{"key":"744_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","volume":"12","author":"C Lally","year":"2017","unstructured":"Lally C, Jones C, Farwell W, et al. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet J Rare Dis. 2017;12:175.","journal-title":"Orphanet J Rare Dis"},{"key":"744_CR23","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","volume":"27","author":"EF Tizzano","year":"2017","unstructured":"Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul Disord. 2017;27:883\u20139.","journal-title":"Neuromuscul Disord"},{"key":"744_CR24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","volume":"5","author":"J Glascock","year":"2018","unstructured":"Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5:145\u201358.","journal-title":"J Neuromuscul Dis"},{"key":"744_CR25","unstructured":"Australian Government. Services Australia. Pharmaceutical benefits schedule item reports, 26 September 2024. http:\/\/medicarestatistics.humanservices.gov.au\/statistics\/pbs_item.jsp. Accessed Oct 2024."},{"key":"744_CR26","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, et al. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Mark Access Health Policy. 2019;7:1601484.","journal-title":"J Mark Access Health Policy"},{"key":"744_CR27","unstructured":"Institute for Clinical and Economic Review (ICER). Spinraza\u00ae and Zolgensma\u00ae for spinal muscular atrophy: effectiveness and value. Final evidence report, 24 May 2019. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SMA_Final_Evidence_Report_052419.pdf. Accessed Oct 2024."},{"key":"744_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12962-020-00234-8","volume":"18","author":"P Thokala","year":"2020","unstructured":"Thokala P, Stevenson M, Kumar VM, et al. Cost-effectiveness of nusinersen for patients with infantile-onset spinal muscular atrophy in US. Cost Eff Resour Alloc. 2020;18:41.","journal-title":"Cost Eff Resour Alloc"},{"key":"744_CR29","doi-asserted-by":"publisher","first-page":"1889841","DOI":"10.1080\/20016689.2021.1889841","volume":"9","author":"R Dean","year":"2021","unstructured":"Dean R, Jensen I, Cyr P, et al. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma\u00ae) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). J Mark Access Health Policy. 2021;9:1889841.","journal-title":"J Mark Access Health Policy"},{"key":"744_CR30","unstructured":"Australian Government. Department of Health and Aged Care. Pharmaceutical Benefits Scheme (PBS). 2024. https:\/\/www.pbs.gov.au\/pbs\/home. (viewed August 2024)."},{"key":"744_CR31","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s40120-023-00489-2","volume":"12","author":"D Weidlich","year":"2023","unstructured":"Weidlich D, Servais L, Kausar I, et al. Cost-effectiveness of newborn screening for spinal muscular atrophy in England. Neurol Ther. 2023;12:1205\u201320.","journal-title":"Neurol Ther"},{"key":"744_CR32","unstructured":"Australian Bureau of Statistics. National, state and territory population, June 2023, 14 December 2023. https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/jun-2023. Accessed Mar 2024."},{"key":"744_CR33","unstructured":"World Health Organization Multicentre Reference Study (WHO MGRS). Child Growth Standards. 1999. https:\/\/www.who.int\/tools\/child-growth-standards\/who-multicentre-growth-reference-study. Accessed Jan 2025."},{"key":"744_CR34","unstructured":"World Health Organization Multicentre Growth Reference Study (WHO MGRS). Window of achievement for six gross motor milestones, 2006. https:\/\/cdn.who.int\/media\/docs\/default-source\/child-growth\/child-growth-standards\/indicators\/motor-development-milestones\/mm_windows_graph.pdf?sfvrsn=ea3a0241_5 (viewed January 2025)."},{"key":"744_CR35","unstructured":"Spinal Muscular Atrophy Australia Inc. SMA Information Guide, 2024. https:\/\/smaaustralia.org.au\/wp-content\/uploads\/SMA_2020_A4_Information_Guide-compressed.pdf (viewed January 2025)."},{"key":"744_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nmd.2024.03.005","volume":"37","author":"L Li","year":"2024","unstructured":"Li L, Menezes MP, Smith M, et al. Rare homozygous disease-associated sequence variants in children with spinal muscular atrophy: a phenotypic description and review of the literature. Neuromuscul Disord. 2024;37:29\u201335.","journal-title":"Neuromuscul Disord"},{"key":"744_CR37","unstructured":"Independent Hospital and Aged Care Pricing Authority. National efficient price determination 2023- 24, 6 March 2023 https:\/\/www.ihacpa.gov.au\/resources\/national-efficient-price-determination-2023-24 (viewed October 2024)."},{"key":"744_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13023-020-01498-2","volume":"15","author":"L Belter","year":"2020","unstructured":"Belter L, Cruz R, Jarecki J. Quality of life data for individuals affected by spinal muscular atrophy: a baseline dataset from the cure SMA community update survey. Orphanet J Rare Dis. 2020;15:217.","journal-title":"Orphanet J Rare Dis"},{"key":"744_CR39","unstructured":"Spinraza\u00ae and Zolgensma\u00ae for spinal muscular atrophy: effectiveness and value\u2014final evidence report. Institute for Clinical and Economic Review. 2019."},{"key":"744_CR40","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000009715","volume":"95","author":"GM Chambers","year":"2020","unstructured":"Chambers GM, Settumba SN, Carey KA, et al. Prenusinersen economic and health-related quality of life burden of spinal muscular atrophy. Neurology. 2020;95:e1\u201310.","journal-title":"Neurology"},{"key":"744_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","volume":"13","author":"R Ara","year":"2010","unstructured":"Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health. 2010;13:509\u201318.","journal-title":"Value Health"},{"key":"744_CR42","unstructured":"Australian Government. Department of Health and Aged Care. About newborn bloodspot screening, 27 June 2023. https:\/\/www.health.gov.au\/our-work\/newborn-bloodspot-screening\/about. Accessed Sept 2024."},{"key":"744_CR43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41436-019-0673-0","volume":"22","author":"DST Kariyawasam","year":"2020","unstructured":"Kariyawasam DST, Russell JS, Wiley V, et al. The implementation of newborn screening for spinal muscular atrophy: the Australian experience. Genet Med. 2020;22:557\u201365.","journal-title":"Genet Med"},{"key":"744_CR44","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jpeds.2017.06.042","volume":"190","author":"YH Chien","year":"2017","unstructured":"Chien YH, Chiang SC, Weng WC, et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr. 2017;190:124-129.e1.","journal-title":"J Pediatr"},{"issue":"3","key":"744_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol. 2018;25(3):512\u20138.","journal-title":"Eur J Neurol"},{"issue":"15 Suppl","key":"744_CR46","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1212\/WNL.94.15_supplement.1640","volume":"94","author":"D Castro","year":"2020","unstructured":"Castro D, Finkel RS, Farrar MA, et al. Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study (1640). Neurology. 2020;94(15 Suppl):1640.","journal-title":"Neurology"},{"key":"744_CR47","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29:842\u201356.","journal-title":"Neuromuscul Disord"},{"key":"744_CR48","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1\/2 studies. Neurology. 2019;92:e2492\u2013506.","journal-title":"Neurology"},{"key":"744_CR49","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard A, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2019;54:179\u201385.","journal-title":"Pediatr Pulmonol"},{"key":"744_CR50","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20:832\u201341.","journal-title":"Lancet Neurol"},{"key":"744_CR51","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28:1381\u20139.","journal-title":"Nat Med"},{"key":"744_CR52","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28:1390\u20137.","journal-title":"Nat Med"},{"key":"744_CR53","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384:915\u201323.","journal-title":"N Engl J Med"},{"key":"744_CR54","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/j.nmd.2020.08.258","volume":"30","author":"G Baranello","year":"2020","unstructured":"Baranello G, Bloespflug-Tanguy O, Darras B, et al. P.259 FIREFISH part 1: 24-month safety and exploratory outcomes of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA). Neuromuscul Disord. 2020;30:S122.","journal-title":"Neuromuscul Disord"},{"issue":"15Suppl","key":"744_CR55","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.94.15_supplement.1302","volume":"94","author":"L Servais","year":"2020","unstructured":"Servais L, Baranello G, Masson R, et al. FIREFISH part 2: efficacy and safety of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA) (1302). Neurology. 2020;94(15Suppl):1302.","journal-title":"Neurology"},{"key":"744_CR56","unstructured":"Servais L, Bloespflug-Tanguy O, Darras B, et al. FIREFISH Parts 1 and 2: 12-month pooled safety and efficacy outcomes of risdiplam (RG7916) in infants with type 1 spinal muscular atrophy (SMA). Presented at the 25th International Annual Congress of the World Muscle Society; 28 September\u20132 October 2020."},{"key":"744_CR57","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1651-2227.2006.tb02378.x","volume":"450","author":"World Health Organization Multicentre Growth Reference Study Group (WHO MGRS)","year":"2006","unstructured":"World Health Organization Multicentre Growth Reference Study Group (WHO MGRS). WHO Child Growth Standards based on length\/height, weight and age. Acta Paediatr Suppl. 2006;450:76\u201385.","journal-title":"Acta Paediatr Suppl"},{"key":"744_CR58","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ, et al. Five-year extension results of the Phase 1 START trial of onasemnogene abeparvovec in spinal muscular atrophy. JAMA Neurol. 2021;78:834\u201341.","journal-title":"JAMA Neurol"},{"key":"744_CR59","doi-asserted-by":"publisher","first-page":"e1509","DOI":"10.1542\/peds.2012-2278","volume":"131","author":"C Gregoretti","year":"2013","unstructured":"Gregoretti C, Ottonello G, Testa MBC, et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics. 2013;131:e1509\u201314.","journal-title":"Pediatrics"},{"key":"744_CR60","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, et al. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146:67\u201372.","journal-title":"J Neurol Sci"},{"key":"744_CR61","unstructured":"Australian Bureau of Statistics. 2019\u20132021 life tables, 8 November 2022. https:\/\/www.abs.gov.au\/statistics\/people\/population\/life-expectancy\/2019-2021. Accessed Oct 2024."},{"key":"744_CR62","unstructured":"Victorian Clinical Genetics Services. Spinal muscular atrophy, 2024. https:\/\/www.vcgs.org.au\/tests\/spinal-muscular-atrophy\/. Accessed Sept 2024."},{"key":"744_CR63","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/jpc.12291","volume":"49","author":"B Tassie","year":"2013","unstructured":"Tassie B, Isaacs D, Kilham H, Kerridge I. Management of children with spinal muscular atrophy type 1 in Australia. J Paediatr Child Health. 2013;49:815\u20139.","journal-title":"J Paediatr Child Health"},{"issue":"suppl1","key":"744_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13696998.2021.2013676","volume":"24","author":"G Chen","year":"2021","unstructured":"Chen G, Sharif B, Gerber B, et al. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada. J Med Econ. 2021;24(suppl1):51\u20139.","journal-title":"J Med Econ"},{"key":"744_CR65","doi-asserted-by":"publisher","first-page":"185","DOI":"10.36469\/63185","volume":"6","author":"H Tan","year":"2019","unstructured":"Tan H, Gu T, Chen E, et al. Healthcare utilization, costs of care, and mortality among patients with spinal muscular atrophy. J Health Econ Outcomes Res. 2019;6:185\u201395.","journal-title":"J Health Econ Outcomes Res"},{"key":"744_CR66","unstructured":"Toro W, Patel A, Aball\u00e9a S, et al. Burden of spinal muscular atrophy type 1 on caregivers in the United States: first results of a global survey. Poster presented at the 2022 Muscular Dystrophy Association Clinical & Scientific Congress; March 13\u201316 2022; Nashville, TN, USA."},{"key":"744_CR67","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-016-0424-0","volume":"11","author":"C Klug","year":"2016","unstructured":"Klug C, Schreiber-Katz O, Thiele S, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11:58.","journal-title":"Orphanet J Rare Dis"},{"key":"744_CR68","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103\u201315.","journal-title":"Neuromuscul Disord"},{"key":"744_CR69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","volume":"28","author":"RS Finkel","year":"2018","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28:197\u2013207.","journal-title":"Neuromuscul Disord"},{"key":"744_CR70","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11136-023-03558-z","volume":"33","author":"L Redwood","year":"2024","unstructured":"Redwood L, Currow D, Kochovska S, Thomas SJ. Australian population norms for health-related quality of life measured using the EQ-5D-5L, and relationships with sociodemographic characteristics. Qual Life Res. 2024;33:721\u201333.","journal-title":"Qual Life Res"},{"key":"744_CR71","unstructured":"Australian Government. Department of Health and Aged Care. Newborn bloodspot screening\u2014national policy framework. 2024. https:\/\/www.health.gov.au\/resources\/publications\/newborn-bloodspot-screening-national-policy-framework?language=en. Accessed Oct 2024."},{"issue":"suppl 1","key":"744_CR72","doi-asserted-by":"publisher","first-page":"S238","DOI":"10.1016\/j.jval.2020.04.805","volume":"23","author":"R Arjunji","year":"2020","unstructured":"Arjunji R, Zhou J, Patel A, et al. PMU30 cost-effectiveness analysis of newborn screening for spinal muscular atrophy (SMA) in the United States. Value Health. 2020;23(suppl 1):S238.","journal-title":"Value Health"},{"key":"744_CR73","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jpeds.2020.07.033","volume":"227","author":"A Jalali","year":"2020","unstructured":"Jalali A, Rothwell E, Botkin JR, et al. Cost-effectiveness of nusinersen and universal newborn screening for spinal muscular atrophy. J Pediatr. 2020;227:274-280.e2.","journal-title":"J Pediatr"},{"key":"744_CR74","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40261-024-01386-8","volume":"44","author":"G Ghetti","year":"2024","unstructured":"Ghetti G, Mennini FS, Marcellusi A, et al. Cost-effectiveness analysis of newborn screening for spinal muscular atrophy in Italy. Clin Drug Investig. 2024;44:687\u2013701.","journal-title":"Clin Drug Investig"},{"key":"744_CR75","unstructured":"Weidlich D, O\u2019Rourke D, Bischof M. Cost-effectiveness analysis of heel prick screening test for spinal muscular atrophy in Ireland. PC98. Presented at the 3rd International Scientific Congress on Spinal Muscular Atrophy, October 21\u201323, 2022, Barcelona, Spain."},{"key":"744_CR76","unstructured":"Santos M, Vieira JP, Ribeiro J, et al. Cost-effectiveness analysis of newborn screening for spinal muscular atrophy in Portugal. PC99. Presented at the 3rd International Scientific Congress on Spinal Muscular Atrophy, October 21\u201323, 2022, Barcelona, Spain."},{"key":"744_CR77","unstructured":"Uda A, Tanaka S, Hata A, et al. Cost-effectiveness analysis of newborn screening for spinal muscular atrophy in Japan. PC96. Presented at the 3rd International Scientific Congress on Spinal Muscular Atrophy, October 21\u201323, 2022, Barcelona, Spain."},{"key":"744_CR78","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.vhri.2023.11.004","volume":"40","author":"BD Fernandes","year":"2024","unstructured":"Fernandes BD, D\u2019Athayde Rodrigues F, Cardoso Cirilo HN, et al. Cost-effectiveness of onasemnogene abeparvovec compared with nusinersen and risdiplam in patients with spinal muscular atrophy type 1 in Brazil: Custo-Efetividade do Onasemnogeno Abeparvoveque (AVXS-101) em Compara\u00e7\u00e3o ao Nusinersena e Risdiplam em Pacientes com Atrofia Muscular Espinhal Tipo 1 no Brasil. Value Health Reg Issues. 2024;40:108\u201317.","journal-title":"Value Health Reg Issues"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00744-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00744-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:03:28Z","timestamp":1747652608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00744-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,27]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["744"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00744-8","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,27]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ian R. Woodcock has received honoraria for work performed with Novartis, Biogen, Roche, Avidity and Pfizer. Damian Clark and Didu S. Kariyawasam, have nothing to disclose. Nicholas J.C. Smith has been an invited member of the Novartis Australian SMA advisory Group; he has received consulting fees from Forge Biologics and Actelion Pharmaceuticals and Research support from Abeona Therapeutics, Ultragenyx, Bluebird bio and Cyclo Therapeutics. Maina P. Kava has received an honorarium for participation in a scientific advisory board for Roche. Eppie M. Yiu has received honoraria from Biogen and Roche for participation in scientific advisory boards, honoraria from Biogen paid to their institution for participation in educational activities, and research support from Biogen, Roche, and Novartis. Matthias Bischof and Jane Adams are employees of Novartis and own Novartis stock or other equities. Adrian Peacock is an employee of HTANALYSTS, which undertakes paid health economics consultancy work for industry and Government. Colman Taylor received grants\/contracts through the George Institute for Global Health from the Baxter Healthcare Corporation and worked as a consultant providing project oversight for a government review of chemotherapy funding; received grants through the George Institute for Global Health from CSL Bioplasma to conduct the FLUID-TRIPS study; received a grant through the George Institute for Global Health from the National Health and Medical Research Council to fund the PLUS study. He is also co-owner of Health Technology Analysts Pty Ltd (HTANALYSTS), which undertakes consultancy work for pharmaceutical companies, medical device companies, not-for-profit entities, and the Australian Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on a cost-utility analysis using a combination of decision tree and Markov model structures. No new studies with human participants were included in this analysis, and, therefore, Institutional Review Board approval was not required, patient consent to participate was not necessary, and the Declaration of Helsinki 1964 does not apply.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}